Descargar la presentación
La descarga está en progreso. Por favor, espere
Publicada porAmparo Ramírez Castellanos Modificado hace 7 años
1
Hepatitis C virus core antigen in the management of patients treated with new direct- acting antivirals Juan Carlos Alados Arboledas, Inmaculada Pavón Guerrero, María José Blanco Rodríguez, Eva Torres Martos, Ana Belén Pérez, Cristina Cepero León, Jesus F. Sierra Sánchez, María Dolores López Prieto, Natalia Chueca Porcuna, María Dolores Ocete Mochón, Juan Macías, Alberto de la Iglesia Salgado, Javier Rodríguez Granger, Marcial Delgado Fernández, Inmaculada Guerrero Lozano, Elena Reigadas Ramírez, Antonio Rivero, María del Carmen Lozano Domínguez, Isabel Viciana, Juan Carlos Galán Montemayor, Federico García García Diagnostic Microbiology and Infectious Disease Volume 89, Issue 1, Pages (September 2017) DOI: /j.diagmicrobio Copyright © 2017 Elsevier Inc. Terms and Conditions
2
Fig. 1 A. HCV RNA kinetics (log IU/mL) in responders (SVR12) and treatment failures B. HCV Ag kinetics (log fmol/L) in responders (SVR12) and treatment failures. Diagnostic Microbiology and Infectious Disease , 29-34DOI: ( /j.diagmicrobio ) Copyright © 2017 Elsevier Inc. Terms and Conditions
3
Fig. 1 A. HCV RNA kinetics (log IU/mL) in responders (SVR12) and treatment failures B. HCV Ag kinetics (log fmol/L) in responders (SVR12) and treatment failures. Diagnostic Microbiology and Infectious Disease , 29-34DOI: ( /j.diagmicrobio ) Copyright © 2017 Elsevier Inc. Terms and Conditions
Presentaciones similares
© 2025 SlidePlayer.es Inc.
All rights reserved.